What Clinical Trials Can Teach Us about the Development of More Resilient AI for Cybersecurity

TL;DR

This paper argues that rigorous, policy-driven clinical trial models from medicine can improve the development and evaluation of resilient AI cybersecurity tools, emphasizing transparency and prioritization of research.

Contribution

It introduces a novel framework inspired by biomedical clinical trials to enhance AI cybersecurity development and evaluation processes.

Findings

Proposes a clinical trial-inspired model for AI cybersecurity evaluation

Highlights the importance of transparency in AI tool efficacy

Draws parallels between biomedical and cybersecurity development processes

Abstract

Policy-mandated, rigorously administered scientific testing is needed to provide transparency into the efficacy of artificial intelligence-based (AI-based) cyber defense tools for consumers and to prioritize future research and development. In this article, we propose a model that is informed by our experience, urged forward by massive scale cyberattacks, and inspired by parallel developments in the biomedical field and the unprecedentedly fast development of new vaccines to combat global pathogens.